Please login to the form below

Not currently logged in
Email:
Password:

Acthar

This page shows the latest Acthar news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offloads CDMO for $250m

Mallinckrodt offloads CDMO for $250m

This will likely include the active ingredient for Acthar, which the pharma company has faced criticism for due to its inflated pricing. ... US health insurer Humana recently filed a lawsuit against Mallinckrodt, alleging that it overpaid $700m for Acthar

Latest news

  • Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose' Humana lawsuit targets Mallinckrodt's 'billion-dollar golden goose'

    The nonprofit allegedly used money from Mallinckrodt to provide patient assistance funds solely for Acthar. ... Over the decades, other drugs superseded Acthar in many, but not all, indications, culminating in Aventis Pharmaceuticals selling the asset to

  • Mallinckrodt pays $1.2bn for Sucampo Pharma Mallinckrodt pays $1.2bn for Sucampo Pharma

    Mallinckrodt is trying to reduce its reliance on cash cow product Acthar (corticotropin) for infantile spasms and multiple sclerosis, which brought in sales of almost $309m in the third quarter of ... Acthar’s slowdown has been attributed by the

  • Ireland's Mallinckrodt buys US regenerative medicine firm Ireland's Mallinckrodt buys US regenerative medicine firm

    Ikaria. . In the previous year it shelled out $5.6bn for Questcor Pharma - getting hold of fast-growing autoimmune and inflammatory drug Acthar (repository corticotropin injection) - and another $1.3bn for

  • Mallinckrodt cuts $5.6bn deal to buy Questcor Mallinckrodt cuts $5.6bn deal to buy Questcor

    Acthar (repository corticotropin injection) grew almost 50 per cent last year to bring in revenues of $799m and accounts for substantially all of Questcor's revenues and profits. ... Questcor has responded by saying that Acthar is a naturally-derived,

  • Scratching the surface

    Restinosis. EU. Corticotropin . Acthar gel (Questcor). Infantile spasms. US. Dabigatran etexilate mesylate.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Acthar sales grew by 50% in 2013 to $761.3m and is predicted to rise to $1.9bn in 2018. Questcor also provides contract manufacturing services through its subsidiary BioVectra. ... Acthar complements Mallinckrodt's portfolio of specialty pharmaceutical

  • Pharma deals during February 2014 Pharma deals during February 2014

    in litigation over two synthetic versions of Acthar (ACTH), a corticotropin with 19 indications, many in rare diseases including infantile spasms, MS, nephrology, and rheumatology.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Questcor appoints SVP corporate strategic development Questcor appoints SVP corporate strategic development

    These moves could see it expand outside the US with its lead product HP Acthar Gel  (repository corticotropin injection), an injectable drug, which is approved by the FDA in several indications ... Development programmes that complement Acthar are also

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics